Precision BioSciences Inc

Financials

Cash from operating activities 87.39 M10.85 M45.75 M84.11 M58.45 M 73.28 M Cash from investing activities 5.03 M5.8 M3.32 M5.83 M215 K 406 K Cash from financing activities 1.33 M70.52 M94.98 M5.39 M50.45 M 23.57 M Free cash flow 82.36 M5.8 M42.43 M82.16 M58.2 M 73.11 M

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences Inc

新闻

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

Precision Biosciences首席财务官出售价值6.13万美元股票

Scimeca，Precision Bio总法律顾问，出售价值$35,681的DTIL股票

Precision Biosciences首席研究官Smith出售价值4.1万美元股票

Precision Biosciences CFO sells $61k in shares

Scimeca, Precision Bio general counsel, sells $35,681 in DTIL stock

Precision Biosciences chief research officer Smith sells $41k in shares

Precision BioSciences推进基因编辑项目，达成关键里程碑

Precision BioSciences advances gene editing programs with key milestones

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL)

Precision Biosciences: Still Swinging And Finally Drawing Blood (NASDAQ:DTIL)